Compare ATR & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATR | CYTK |
|---|---|---|
| Founded | 1992 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1B | 7.6B |
| IPO Year | 1995 | 2004 |
| Metric | ATR | CYTK |
|---|---|---|
| Price | $121.37 | $66.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | ★ $170.25 | $89.26 |
| AVG Volume (30 Days) | 401.2K | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ 6.51 | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $3,777,181,000.00 | $13,368,000.00 |
| Revenue This Year | $5.18 | $7.37 |
| Revenue Next Year | $4.98 | $310.19 |
| P/E Ratio | $108.06 | ★ N/A |
| Revenue Growth | ★ 5.42 | N/A |
| 52 Week Low | $103.23 | $29.31 |
| 52 Week High | $164.28 | $70.98 |
| Indicator | ATR | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 56.82 |
| Support Level | $118.91 | $59.12 |
| Resistance Level | $125.35 | $70.23 |
| Average True Range (ATR) | 3.81 | 2.56 |
| MACD | -0.64 | -0.12 |
| Stochastic Oscillator | 27.32 | 91.29 |
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.